Cambridge Investment Research Advisors, Inc. Fibrogen Inc Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$7.94 - $12.96 $84,410 - $137,777	-10,631 Closed	0 $0
Q4 2021 Feb 03, 2022	SELL	$9.93 - $15.39 $1,986 - $3,078	-200 Reduced 1.85%	10,631 $149,000
Q3 2021 Nov 02, 2021	BUY	$10.18 - $26.64 $110,259 - $288,537	10,831 New	10,831 $110,000
Q2 2021 Aug 10, 2021	SELL	$18.57 - $35.68 $111,420 - $214,080	-6,000 Closed	0 $0
Q1 2021 May 07, 2021	SELL	$31.0 - $55.72 $77,500 - $139,300	-2,500 Reduced 29.41%	6,000 $208,000
Q4 2020 Feb 04, 2021	SELL	$37.09 - $48.97 $74,513 - $98,380	-2,009 Reduced 19.12%	8,500 $315,000
Q3 2020 Oct 29, 2020	SELL	$40.47 - $45.5 $39,458 - $44,362	-975 Reduced 8.49%	10,509 $432,000
Q2 2020 Jul 27, 2020	BUY	$32.57 - $42.83 $4,364 - $5,739	134 Added 1.18%	11,484 $465,000
Q1 2020 May 08, 2020	SELL	$23.3 - $45.96 $2,050 - $4,044	-88 Reduced 0.77%	11,350 $394,000
Q4 2019 Feb 04, 2020	BUY	$34.58 - $48.06 $9,959 - $13,841	288 Added 2.58%	11,438 $490,000
Q2 2019 Aug 15, 2019	BUY	$35.13 - $55.53 $391,699 - $619,159	11,150 New	11,150 $0

Others Institutions Holding FGEN

# of Institutions

Shares Held

47.1M

Call Options Held

387K

Put Options Held

672K

Primecap Management CO Pasadena, CA

9.91M
Shares

$3.47 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

6.8M
Shares

$2.38 Million
0.05% of portfolio
Vanguard Group Inc Valley Forge, PA

5.88M
Shares

$2.06 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

3.91M
Shares

$1.37 Million
0.0% of portfolio
Black Rock Inc. New York, NY

2.41M
Shares

$843,377
0.0% of portfolio

View Full List

About FIBROGEN INC

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

More about FGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account